This text is a result of machine translation.
F-star to be acquired by China biopharmaceutical with USD 161million
"Delisting warning" of Whitson pharmaceuticals on the New York Stock Exchange
BeiGene: a Vast Opportunity Lies Ahead – But We Remain Cautious
BeiGene, a leader in China's novel pharmaceutical industry, recently received approval in Kuwait, Bahrain, and Qatar for its medication BRUKINSA (zanubrutinib). Previous contracts with major biopharma have produced substantial licensing income, but they did not lessen BeiGene's financial burden.
Jun 24, 2022 12:13 PM
East China medicine "liraglutide" goes to sea
Research
Technology, Healthcare, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Research
Technology, Real Estate, IndustrialsTech for Global, Globalization Footprints of the Established and the New
Research
Technology, Real Estate, IndustrialsLow-Carbon Industry Expansion - Key Studies From Chinese Companies
Nearly half of the equity of two subsidiaries of Tongrentang was transferred to Tongrentang medical care
Baiyunshan: suspension of the spin off of Guangzhou Pharmaceutical for overseas listing
Germany Merck "cetuximab" new indications for head and neck squamous cell carcinoma approved in China
Yanye new crown drug 3CL protein inhibitor has been suspended approval
Dialysis Provider Dakang Medical Raised CNY 400 Million Yuan in Series E Round.
This financing round was led by Ganjiang Kai Investment, a state-owned investment platform in Ganjiang, Jiangxi Province, and was followed by Central Enterprises Poor Regions Industry Investment Fund Co., and Neovision Capital.
Yesterday 04:16 PM
Sanofi Greater China will be headed by Shi Wang, and Henting he will become the global head of the digital business unit
Acadia Alzheimer's drug SNDA application rejected by FDA advisory committee
Huashen Zhiyao completed nearly 500million yuan of a-round financing and went deep into AI new drug development
Biotech Firm ImmuneOnco Submitted Listing Application on the Main Board of HKEX
ImmuneOnco, focusing on developing new-generation tumor immunotherapeutic, will further accelerate the development of other promising drug candidates targeting checkpoints of innate and adaptive immunity.
Jun 28, 2022 10:58 PM
Lvzhu Biopharmaceutical's Completed its Third Funding Round of The Year
Lvzhu finished its Series C funding round, marking its success of gaining three funding rounds within 12 months. Its exploration of listing in Hong Kong Stock Exchange marks the company's potential, as supported by CICC.
Jun 28, 2022 02:47 PM
Huamei Haolian, a health management service enterprise, completed round a+ financing, and Jinshajiang venture capital led the investment
Mojia biology announced the completion of round B financing
First class recall of Draeger, a ventilator giant
The state plans to prohibit third-party platforms from directly participating in online drug sales
EqualOcean Series: China VC Investment List Q2 2022
Yesterday 05:36 PM